Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Australian Red Cross Blood Service

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the supply and manufacture of therapeutic goods to ensure they are safe, of high quality, and effective. This Act addresses the need for stringent control over the therapeutic goods market to protect public health. As part of its regulatory framework, the Act empowers the Secretary to revoke the licences of manufacturers who no longer meet the required standards or have requested such revocation. This recent revocation of the licence held by the Australian Red Cross Blood Service – an operating division of the Australian Red Cross Society, specifically the Victorian Transplantation and Immunogenetics Service – highlights the ongoing commitment to maintaining high standards within the therapeutic goods industry. The policy objective is to ensure that only entities capable of maintaining the required standards are permitted to manufacture and supply therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, importation, and advertising of therapeutic goods in Australia. The Act covers a broad spectrum of therapeutic goods including medicines, medical devices, blood, and tissues. It applies to individuals, corporations, and other legal entities that engage in activities related to these goods, thereby ensuring they meet specific quality, safety, and efficacy standards. The jurisdiction of the Act is national, extending across all states and territories of Australia, thereby creating a unified regulatory framework for therapeutic goods. In this specific instance, the Act's application is evidenced by the revocation of a licence held by the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, for the manufacture of therapeutic goods. This revocation was carried out under the authority granted by the Act and was carried out by Bill Turner, the delegate of the Secretary. The geographic scope of the Act is clear in this context, as the revocation pertains to a facility located in Royal Parade, Parkville, Victoria. There are no exclusions or exemptions mentioned in this particular revocation notice, indicating that the Act's provisions are uniformly applied.

Key Provisions

The Therapeutic Goods Act 1989 provides the framework for regulating therapeutic goods in Australia. Specifically, section 41(1)(d) (paragraph d of subsection 1 of section 41) allows the Secretary to revoke a manufacturer's licence upon written notice, as seen in the case of the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, Victorian Transplantation and Immunogenetics Service. This section empowers the Secretary to take action to ensure the safety and quality of therapeutic goods in Australia. The revocation of the licence number MI-20042007-LI-001833-11, held by the Rotary Bone Marrow Research Centre, was carried out at the request of the manufacturer, further indicating the Act's flexibility in responding to circumstances that might compromise the integrity of therapeutic goods. The revocation of a licence under the Therapeutic Goods Act 1989 imposes specific obligations on the entities governed by the Act. The affected manufacturer, in this case, the Rotary Bone Marrow Research Centre, must cease all manufacturing activities immediately upon receiving notification of the revocation. The Act requires that the manufacturer ensure that all therapeutic goods produced under the revoked licence are either recalled, destroyed, or otherwise dealt with in a manner that prevents their further distribution or use. Additionally, the manufacturer must provide any necessary information or records to the Secretary to assist in the oversight and regulatory processes. Failure to comply with these obligations can lead to further regulatory action. Breach of the provisions of the Therapeutic Goods Act 1989 can result in significant legal consequences. Under the Act, unauthorised manufacturing of therapeutic goods can be considered an offence. The Act does not specify exact penalties in the context of this notice but generally, offences under the Act can lead to substantial fines and, in severe cases, imprisonment. The maximum penalties for offences under the Act can vary but often include fines up to $1.1 million for corporations and imprisonment for up to five years for individuals. These penalties underscore the importance of compliance with the Act to maintain the safety and quality of therapeutic goods in Australia.